信达生物玛仕度肽获批糖尿病适应证

Core Viewpoint - The company Sinopharm Biologics announced that its product, Masitide Injection, has received approval from the National Medical Products Administration for a new indication to control blood sugar in adults with type 2 diabetes, making it the world's first dual receptor agonist for GCG/GLP-1 in diabetes treatment [1] Group 1 - The new indication approval follows the previous approval in June for weight loss, marking the second indication for the drug this year [1]